Cwm LLC Has $181,000 Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Cwm LLC lessened its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 7.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 12,301 shares of the company’s stock after selling 997 shares during the period. Cwm LLC’s holdings in Elanco Animal Health were worth $181,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in ELAN. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Elanco Animal Health by 337.7% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock worth $26,000 after buying an additional 1,361 shares in the last quarter. nVerses Capital LLC acquired a new position in shares of Elanco Animal Health in the second quarter valued at about $32,000. ORG Partners LLC bought a new position in Elanco Animal Health during the second quarter worth about $31,000. Quarry LP acquired a new stake in Elanco Animal Health in the 2nd quarter worth about $40,000. Finally, Global Financial Private Client LLC bought a new stake in Elanco Animal Health in the 1st quarter valued at about $72,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Trading Down 1.2 %

NYSE ELAN opened at $12.51 on Thursday. The company has a current ratio of 2.93, a quick ratio of 1.75 and a debt-to-equity ratio of 0.92. The firm has a market capitalization of $6.18 billion, a P/E ratio of -4.77, a PEG ratio of 1.53 and a beta of 1.40. The business has a fifty day simple moving average of $14.43 and a 200 day simple moving average of $14.85. Elanco Animal Health Incorporated has a 12 month low of $8.52 and a 12 month high of $18.80.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.06. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. The firm had revenue of $1.18 billion during the quarter, compared to the consensus estimate of $1.15 billion. During the same quarter in the prior year, the company earned $0.18 EPS. The business’s revenue for the quarter was up 12.0% on a year-over-year basis. On average, analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Insider Transactions at Elanco Animal Health

In related news, CEO Jeffrey N. Simmons purchased 100,000 shares of the business’s stock in a transaction on Monday, August 12th. The stock was acquired at an average price of $13.01 per share, with a total value of $1,301,000.00. Following the purchase, the chief executive officer now directly owns 145,000 shares in the company, valued at approximately $1,886,450. This represents a 200.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Elanco Animal Health news, CEO Jeffrey N. Simmons purchased 100,000 shares of Elanco Animal Health stock in a transaction on Monday, August 12th. The shares were acquired at an average cost of $13.01 per share, for a total transaction of $1,301,000.00. Following the completion of the transaction, the chief executive officer now directly owns 145,000 shares of the company’s stock, valued at approximately $1,886,450. The trade was a 200.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Michael J. Harrington acquired 3,500 shares of the stock in a transaction dated Thursday, August 22nd. The stock was acquired at an average price of $14.85 per share, with a total value of $51,975.00. Following the completion of the acquisition, the director now owns 81,094 shares in the company, valued at approximately $1,204,245.90. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. 0.57% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts have weighed in on ELAN shares. Barclays lifted their price objective on Elanco Animal Health from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Monday, September 23rd. Morgan Stanley downgraded Elanco Animal Health from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $17.00 to $15.00 in a research note on Thursday, September 19th. Stifel Nicolaus reiterated a “buy” rating and set a $20.00 price objective on shares of Elanco Animal Health in a research note on Thursday, September 19th. Finally, Piper Sandler dropped their target price on shares of Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating for the company in a research report on Monday, July 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $17.43.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.